Cited by 55Amyotrophic Lateral Sclerosis ResearchAlzheimer's disease research and treatmentsNF-κB Signaling Pathways

Mitigation of ALS Pathology by Neuron-Specific Inhibition of Nuclear Factor Kappa B Signaling

Open access
Dutta, Kallol, Thammisetty, Sai Sampath, Boutej, Hejer, Bareil, Christine, Julien, Jean-Pierre·2020·The Journal of Neuroscience

Abstract

To investigate the role of neuronal NF-κB activity in pathogenesis of amyotrophic lateral sclerosis (ALS), we generated transgenic mice with neuron-specific expression of a super-repressor form of the NF-κB inhibitor (IκBα-SR), which were then crossed with mice of both sexes, expressing ALS-linked gene mutants for TAR DNA-binding protein (TDP-43) and superoxide dismutase 1 (SOD1). Remarkably, neuronal expression of IκBα-SR transgene in mice expressing TDP-43A315T or TDP-43G348C mice led to a decrease in cytoplasmic to nuclear ratio of human TDP-43. The mitigation of TDP-43 neuropathology by IκBα-SR, which is likely due to an induction of autophagy, was associated with amelioration of cognitive and motor deficits as well as reduction of motor neuron loss and gliosis. Neuronal suppression of NF-κB activity in SOD1G93A mice also resulted in neuroprotection with reduction of misfolded SOD1 levels and significant extension of life span. The results suggest that neuronal NF-κB signaling constitutes a novel therapeutic target for ALS disease and related disorders with TDP-43 proteinopathy. SIGNIFICANCE STATEMENT This study reports that neuron-specific expression of IκB super-repressor mitigated behavioral and pathologic changes in transgenic mouse models of amyotrophic lateral sclerosis expressing mutant forms of either Tar DNA-binding protein 43 or superoxide dismutase. The results suggest that neuronal NF-κB signaling constitutes a novel therapeutic target for amyotrophic lateral sclerosis and related disorders with Tar DNA-binding protein 43 proteinopathy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1523/jneurosci.0536-20.2020

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Observations of neuron-derived immune signaling at early stages of neurodegenerative disease indicate that this may play a role in disease progression.

    “Indeed, observations of neuron‐derived immune signaling at early stages of neurodegenerative disease indicate that this may play a role in disease progression (Dutta et al, 2020; Welikovitch et al, 2020).”

    From Mechanisms of DNA damage-mediated neurotoxicity in neurodegenerative disease (2022) · cites this paper as Dutta et al, 2020

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 52 · Cited by 55

Research works printed but not linked: 1

  1. Ögren SO, Stiedl O (2010) Passive avoidance. In: Encyclopedia of psychopharmacology (Stolerman IP, ed), pp 960– 967. Berlin: Springer.

Authors
Dutta, K., Thammisetty, S. S., Boutej, H., Bareil, C., & Julien, J.-P.
Affiliations
  • Centre de recherche CERVO (CA)
  • Université Laval (CA)
Corresponding author
Julien, Jean-Pierre
Venue
The Journal of Neuroscience
Published
2020-05-26
Volume
40
Issue
26
Pages
5137-5154
ISSN
  • 0270-6474 (ISSN-L)
  • 1529-2401
OpenAlex
W3028661192
Cited by
55
References
52
Citations by year
2026: 5 · 2025: 7 · 2024: 5 · 2023: 11 · 2022: 13 · 2021: 12 · 2020: 2
FWCI
4.11
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Journal of Neuroscience (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Fondation Brain Canada
  • Canadian Institutes of Health Research
Topics
  • Health Sciences › Medicine › Neurology › Amyotrophic Lateral Sclerosis Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
Keywords
amyotrophic lateral sclerosis, NF-κB signaling, IκBα super-repressor, neuron-specific gene expression, TDP-43, SOD1 G93A, autophagy, motor neuron degeneration, neuroprotection, TDP-43 proteinopathy, therapeutic target, transgenic mouse model
MeSH terms
NF-KappaB Inhibitor alpha, Superoxide Dismutase-1, Amyotrophic Lateral Sclerosis, Animals, DNA-Binding Proteins, Female, Humans, Male, Mice, Transgenic, Motor Neurons, Signal Transduction, NF-kappa B, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review